Purchase Order HHSO100201600016P

This is a federal contract award from the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Seqirus Inc., a division of CSL Seqirus, a leading global biotechnology company. The contract, valued at $34,163.00, is for the continuation of a physical chemical compatibility study of the H7N9 influenza vaccine with the MF59 adjuvant for an additional 18 months. The contract is a firm fixed-price purchase order with no set-aside designation. Seqirus has been awarded numerous federal contracts from HHS ASPR related to pandemic preparedness and response, including an Indefinite Delivery Contract valued at $13.4 billion to provide medical countermeasures such as vaccines, adjuvants, and related services.